Loading
Every dated change on the records linked to Hepatocellular carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
First CRL: manufacturing inspection findings
Complete response letter for camrelizumab + rivoceranib in HCC (manufacturing/inspection)
OS 23.
PFS HR 0.
PFS HR 0.
A milestone in how this cancer is treated.
First-line unresectable HCC
First-line unresectable hepatocellular carcinoma with camrelizumab (CARES-310)
Universal HBV vaccination; antiviral suppression of HBV; direct-acting antiviral cure of HCV; alcohol and metabolic risk reduction. (NCCN Hepatobiliary Cancers)
Six-monthly ultrasound ± AFP in cirrhosis and high-risk HBV carriers; abbreviated MRI where ultrasound is inadequate.
OS 23.
Interim RFS HR 0.
Weight gain over 5%: 60% vs 9%; appetite improvement 43% vs 13%.
Metastatic NSCLC without EGFR/ALK, with durvalumab and platinum chemotherapy; unresectable HCC with durvalumab
OS HR 0.
OS HR 0.
A milestone in how this cancer is treated.
First-line unresectable hepatocellular carcinoma (ZGDH3)
First-line non-squamous NSCLC with pemetrexed and platinum (ORIENT-11); first-line squamous NSCLC with gemcitabine and platinum (ORIENT-12); first-line unresectable hepatocellular carcinoma with IBI305 (ORIENT-32)
OS HR 0.
OS 12.
Advanced hepatocellular carcinoma after prior systemic therapy
OS 19.
First regimen to improve OS over sorafenib; new standard.
A milestone in how this cancer is treated.
HCC previously treated with sorafenib
Classical Hodgkin lymphoma; subsequently HCC, NSCLC, ESCC (second line 2020, first line with chemotherapy 2021), nasopharyngeal
HCC with AFP ≥400 ng/mL after sorafenib
Classical Hodgkin lymphoma (first); subsequently urothelial, NSCLC, HCC, ESCC, gastric, nasopharyngeal
Ramucirumab improved overall survival over placebo in alpha-fetoprotein-high hepatocellular carcinoma after sorafenib; approved in May 2019.
First-line unresectable HCC
OS 10.
OS 13.
A milestone in how this cancer is treated.
HCC previously treated with sorafenib
OS 10.
OS not improved; fewer adverse events.
A milestone in how this cancer is treated.